Log in

Relevant bibliographies by topics / Parkinson's Disease (AD) / Journal articles

To see the other types of publications on this topic, follow the link: Parkinson's Disease (AD).

Journal articles on the topic 'Parkinson's Disease (AD)'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Parkinson's Disease (AD).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Clarke, C. E. "Parkinson's disease." BMJ 335, no. 7617 (2007): 441–45. http://dx.doi.org/10.1136/bmj.39289.437454.ad.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Jakubiec, Joanna, Julita Gmitrzuk, Zuzanna Malinka, et al. "The Impact of Gut Microbiota on Parkinson’s and Alzheimer’s Diseases: A Review of Medical Literature." Quality in Sport 15 (July 5, 2024): 52004. http://dx.doi.org/10.12775/qs.2024.15.52004.

Full text

Abstract:

Introduction Neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD), pose a major public health challenge due to their progressive nature and profound impact on patients and healthcare systems. Emerging evidence underscores the key role of the gut microbiota in the pathogenesis and progression of these diseases. This paper examines the current state of knowledge on the impact of the gut microbiota on PD and AD, focusing on mechanisms such as modulation of inflammation, blood-brain barrier integrity, neurotransmitter production and amyloid pathology. Future re

APA, Harvard, Vancouver, ISO, and other styles

3

Helsing, Elisabet. "The reluctant patient: Parkinson's disease." BMJ 335, no. 7627 (2007): 989–90. http://dx.doi.org/10.1136/bmj.39329.606840.ad.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Giovannetti, Tania, Priscilla Britnell, Laura Brennan, et al. "Everyday Action Impairment in Parkinson's Disease Dementia." Journal of the International Neuropsychological Society 18, no. 5 (2012): 787–98. http://dx.doi.org/10.1017/s135561771200046x.

Full text

Abstract:

AbstractThis study examined everyday action impairment in participants with Parkinson's disease dementia (PDD) by comparison with participants with Parkinson's disease-no dementia (PD) or Alzheimer's disease (AD) and in reference to a neuropsychological model. Participants with PDD (n = 20), PD (n = 20), or AD (n = 20) were administered performance-based measures of everyday functioning that allowed for the quantification of overall performance and error types. Also, caregiver ratings of functional independence were obtained. On performance-based tests, the PDD group exhibited greater function

APA, Harvard, Vancouver, ISO, and other styles

5

Wang, Yubu. "The Application and Effectiveness of CRISPR-Cas9 in Alzheimer's Disease and Parkinson's Disease." Highlights in Science, Engineering and Technology 102 (July 11, 2024): 514–19. https://doi.org/10.54097/pbjqff61.

Full text

Abstract:

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are both types of neurodegenerative diseases (ND) that lead to severe failure in the nervous system. Usually, AD and PD are caused by genetic or environmental factors, and patients of AD or PD suffer from life inconveniences. AD and PD are both the major causes of irreversible dementia and can be classified into familiar and sporadic. A greater proportion of patients get sporadic AD and PD, and there hasn’t been an effective treatment for the diseases. Widely discussed in the 21st century, it is believed that CRISPR-Cas9 gene therapy may be

APA, Harvard, Vancouver, ISO, and other styles

6

Ma, Xiaoyu, and Juejin Wang. "Research progress on the role of ginsenoside Rd in central nervous system diseases." African Health Sciences 24, no. 4 (2025): 325–31. https://doi.org/10.4314/ahs.v24i4.41.

Full text

Abstract:

Ginsenoside Rd (GSRd) is one of the rare saponin monomers extracted from ginseng. Most importantly, GSRd could effectively cross the intact blood-brain barrier (BBB). Studies have shown that it plays an important role in the treatment of neurological diseases such as ischemic stroke (IS), spinal cord injury (SCI), Alzheimer's disease (AD) and Parkinson's disease (PD). The results of these studies are of great significance for the clinical application of GSRd in the treatment in neurological diseases. This article reviewed the protective effects of GSRd in central nervous system diseases and an

APA, Harvard, Vancouver, ISO, and other styles

7

Oleksak, Izabela, Michał Leśniewski, Iwona Welian-Polus, Karolina Maliszewska, and Joanna Ziółkowska. "Does gut microbiota have an impact on the origin of Alzheimer's and Parkinson's disease? – literature review." Journal of Education, Health and Sport 57 (February 7, 2024): 70–85. http://dx.doi.org/10.12775/jehs.2024.57.005.

Full text

Abstract:

Introduction and purpose: Among neurodegenerative disorders, Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent. It has been observed recently that alterations in the gut microbiota are associated with the onset of neurodegenerative disorders. This research aims to estimate the pathomechanisms and disease courses associated with the gut microbiota that lead to AD and PD development. Material and methods The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included Alzheimer’s disease; Parkinson’s d

APA, Harvard, Vancouver, ISO, and other styles

8

Liu, Meiqiu, Qian Jiao, Xixun Du, Mingxia Bi, Xi Chen, and Hong Jiang. "Potential Crosstalk Between Parkinson's Disease and Energy Metabolism." Aging and disease 12, no. 8 (2021): 2003. http://dx.doi.org/10.14336/ad.2021.0422.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Foley, Jennifer A., Reiner Kaschel, and Sergio Della Sala. "Dual Task Performance in Parkinson’s Disease." Behavioural Neurology 27, no. 2 (2013): 183–91. http://dx.doi.org/10.1155/2013/150361.

Full text

Abstract:

Several studies have found dual tasking to be impaired in Alzheimer's disease (AD), but unaffected by healthy ageing. It is not known if this deficit is specific to AD, or also present in other neurodegenerative disorders that can occur in later life, such as Parkinson's disease (PD). Therefore, this study investigated dual tasking in 13 people with PD, 26 AD and 42 healthy age-matched controls. The people with AD demonstrated a specific impairment in dual tasking, which worsened with increasing disease severity. The people with PD did not demonstrate any deficits in dual tasking ability, when

APA, Harvard, Vancouver, ISO, and other styles

10

Wingo, Thomas S., Ami Rosen, David J. Cutler, James J. Lah, and Allan I. Levey. "Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases." Neurobiology of Aging 33, no. 1 (2012): 204.e13–204.e15. http://dx.doi.org/10.1016/j.neurobiolaging.2010.08.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Salkov, V. N., and R. M. Khudoerkov. "Copper and zinc level alterations in the brain structures in Parkinson’s and Alzheimer’s diseases." CLINICAL AND EXPERIMENTAL MORPHOLOGY 9, no. 3 (2020): 21–26. http://dx.doi.org/10.31088/cem2020.9.3.21-26.

Full text

Abstract:

The article reviews the literature on copper and zinc level alterations in the brain structures in neurodegenera-tive diseases (Parkinson's disease, PD, and Alzheimer's disease, AD). We discuss the ability of these micro-elements to bind to cellular proteins (α-synuclein in PD and β-amyloid in AD) disrupting their metabolism. The literature analysis shows that high copper levels in the neurons of nigrostriatal brain formations in PD initiate oxidative stress development. Copper extracellular deficiency disturbs iron metabolism and thus may increase the stress. Low zinc levels weaken the enzyme

APA, Harvard, Vancouver, ISO, and other styles

12

Huo, Cui, Lei Wu, Zhiqiang Jiang, et al. "Current Research on Pro-drug Therapies for Parkinson's and Alzheimer's Disease." Medicinal Chemistry 18, no. 6 (2022): 655–66. http://dx.doi.org/10.2174/1573406418666211130150821.

Full text

Abstract:

Background: Alzheimer's disease (AD) and Parkinson's (PD) disease are common neurodegenerative conditions of the Central Nervous System (CNS). Thus, these diseases have only been treated symptomatically since no approved drug is available that provides a complete cure. Objectives: Through reading relevant literatures published at home and abroad, the method and significance of prodrug strategy to increase the efficacy of ad and pd drugs were discussed. Methods: The biological mechanisms and currently approved drugs for both diseases have been discussed, revealing that most of these treatments

APA, Harvard, Vancouver, ISO, and other styles

13

Yunqi, Xu, Wei Xiaobo, Liu Xu, et al. "Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson's Disease." Aging and Disease 6, no. 6 (2015): 426. http://dx.doi.org/10.14336/ad.2015.0204.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Heron, Campbell J. Le, Sarah L. Wright, Tracy R. Melzer, et al. "Comparing Cerebral Perfusion in Alzheimer's Disease and Parkinson's Disease Dementia: An ASL-MRI Study." Journal of Cerebral Blood Flow & Metabolism 34, no. 6 (2014): 964–70. http://dx.doi.org/10.1038/jcbfm.2014.40.

Full text

Abstract:

Emerging evidence suggests that Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) share neurodegenerative mechanisms. We sought to directly compare cerebral perfusion in these two conditions using arterial spin labeling magnetic resonance imaging (ASL-MRI). In total, 17 AD, 20 PDD, and 37 matched healthy controls completed ASL and structural MRI, and comprehensive neuropsychological testing. Alzheimer's disease and PDD perfusion was analyzed by whole-brain voxel-based analysis (to assess absolute blood flow), a priori specified region of interest analysis, and principal component

APA, Harvard, Vancouver, ISO, and other styles

15

Tan, Lynnette Pei Lin, Nathan Herrmann, Brian J. Mainland, and Kenneth Shulman. "Can clock drawing differentiate Alzheimer's disease from other dementias?" International Psychogeriatrics 27, no. 10 (2015): 1649–60. http://dx.doi.org/10.1017/s1041610215000939.

Full text

Abstract:

ABSTRACTBackground:Studies have shown the clock-drawing test (CDT) to be a useful screening test that differentiates between normal, elderly populations, and those diagnosed with dementia. However, the results of studies which have looked at the utility of the CDT to help differentiate Alzheimer's disease (AD) from other dementias have been conflicting. The purpose of this study was to explore the utility of the CDT in discriminating between patients with AD and other types of dementia.Methods:A review was conducted using MEDLINE, PsycINFO, and Embase. Search terms included clock drawing or CL

APA, Harvard, Vancouver, ISO, and other styles

16

de la Monte, S. M., and J. R. Wands. "Diagnostic utility of quantitating neurofilament-immunoreactive Alzheimer's disease lesions." Journal of Histochemistry & Cytochemistry 42, no. 12 (1994): 1625–34. http://dx.doi.org/10.1177/42.12.7983363.

Full text

Abstract:

The diagnosis of Alzheimer's disease (AD) neurodegeneration is based on histopathological detection of paired helical filament-associated lesions. Silver stains are routinely used but the results are fraught with intra- and interinstitutional variability. This study employed monoclonal antibodies to middle and high molecular weight neurofilament subunits in an immunohistochemical assay to assess the extent of paired helical filament-associated lesions in brains with AD, Down's syndrome plus AD lesions (AD+DN), Parkinson's disease dementia (PD), AD+PD, and normal aging changes. The densities of

APA, Harvard, Vancouver, ISO, and other styles

17

Van Lancker Sidtis, Diana, JiHee Choi, Amy Alken, and John J. Sidtis. "Formulaic Language in Parkinson's Disease and Alzheimer's Disease: Complementary Effects of Subcortical and Cortical Dysfunction." Journal of Speech, Language, and Hearing Research 58, no. 5 (2015): 1493–507. http://dx.doi.org/10.1044/2015_jslhr-l-14-0341.

Full text

Abstract:

Purpose The production of formulaic expressions (conversational speech formulas, pause fillers, idioms, and other fixed expressions) is excessive in the left hemisphere and deficient in the right hemisphere and in subcortical stroke. Speakers with Alzheimer's disease (AD), having functional basal ganglia, reveal abnormally high proportions of formulaic language. Persons with Parkinson's disease (PD), having dysfunctional basal ganglia, were predicted to show impoverished formulaic expressions in contrast to speakers with AD. This study compared participants with PD, participants with AD, and h

APA, Harvard, Vancouver, ISO, and other styles

18

Starkstein, S. E., S. Vázquez, G. Petracca, L. Sabe, M. Merello, and R. Leiguarda. "SPECT Findings in Alzheimer’s Disease and Parkinson’s Disease with Dementia." Behavioural Neurology 10, no. 4 (1997): 121–27. http://dx.doi.org/10.1155/1997/379683.

Full text

Abstract:

We examined, with single photon emission tomography (SPECT) and (99mTc)-HMPAO, 18 patients with idiopathic Parkinson's disease and no dementia (PD), 12 patients with PD and dementia, 24 patients with probable Alzheimer's disease (AD), and 14 controls. While the three patient groups showed significantly lower perfusion in frontal inferior and temporal inferior areas as compared to controls, both demented groups showed significantly more severe bilateral hypoperfusion in superior frontal, superior temporal and parietal areas as compared to non-demented PD patients and controls. On the other hand

APA, Harvard, Vancouver, ISO, and other styles

19

Angale, Ruth. "The Role of Mitochondria in Alzheimer's disease: Neurodegenerative Disease and Future Therapeutic Options." Neuroscience and Neurological Surgery 2, no. 1 (2018): 01–03. http://dx.doi.org/10.31579/2578-8868/026.

Full text

Abstract:

Mitochondria are cytoplasmic organelles responsible for life and death. Extensive evidence from animal and clinical studies suggests that mitochondria play a critical role in aging, cancer, diabetes and neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Several lines of research suggest that mitochondrial oxidative damage is an important cellular change in most late-onset neurodegenerative diseases. Further, emerging evidence suggests that structural changes in mitochondria, including increased mitochondrial fragmentation and decreased mitoc

APA, Harvard, Vancouver, ISO, and other styles

20

Park, Seha, Shinyoung Song, Seulki Lee, et al. "A Case of Desmoplastic Melanoma in a Patient with Parkinson's Disease." Annals of Dermatology 31, no. 6 (2019): 681. http://dx.doi.org/10.5021/ad.2019.31.6.681.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Bhatia, Madhulika, Amrinder Kaur, Shaveta Bhatia, Mridula, and Pallavi Dwivedi. "Detection of Parkinson’s Disease in Alzheimer’s Patients Utilizing Brain Imaging." Traitement du Signal 39, no. 4 (2022): 1443–51. http://dx.doi.org/10.18280/ts.390439.

Full text

Abstract:

Patients with Alzheimer's infection (AD) and Parkinson's sickness (PD) regularly have cover in clinical show and cognitive neuropathology proposing that these two illnesses share basic fundamental instruments. Parkinson sickness emerges from diminished dopamine creation in the mind. Patients with these two illnesses often cover in clinical introduction and cerebrum neuropathology proposing that they share basic common fundamental systems. Therefore, it become important two find the presence of common affected brain region of interest. The paper proposes the technique to find out the relation b

APA, Harvard, Vancouver, ISO, and other styles

22

Shamei, Arian, Yadong Liu, and Bryan Gick. "Reduction of vowel space in Alzheimer's disease." JASA Express Letters 3, no. 3 (2023): 035202. http://dx.doi.org/10.1121/10.0017438.

Full text

Abstract:

Reduced vowel space area (VSA) is a known effect of neurodegenerative diseases such as Parkinson's disease (PD). Using large publicly available corpuses, two experiments were conducted comparing the vowel space of speakers with and without Alzheimer's disease (AD) during spontaneous and read speech. First, a comparison of vowel distance found reduced distance in AD for English spontaneous speech, but not Spanish read speech. Findings were then verified using an unsupervised learning approach to quantify VSA through cluster center detection. These results corroborate observations for PD that VS

APA, Harvard, Vancouver, ISO, and other styles

23

Outeiro, T. F. "From Mad Cows to Neurotic Yeast: Novel Molecular Approaches to Understand Neurodegeneration." Microscopy and Microanalysis 14, S3 (2008): 105–6. http://dx.doi.org/10.1017/s143192760808954x.

Full text

Abstract:

Aging is the major known risk factor for Alzheimer's disease (AD) and Parkinson's disease (PD), but genetic deffects have been associated with familial cases. Huntington's disease (HD) is a purely genetic neurodegenerative disorder, where mutations in the IT15 gene, encoding for the protein huntingtin, determine the development of the disease. The Prion diseases differ from these other disorders because they can also have infections origin.

APA, Harvard, Vancouver, ISO, and other styles

24

Alamri, Yassar, Tim Anderson, John Dalrymple-Alford, and Michael Macaskill. "Errors on the MoCA's animal-naming: findings from Parkinson's disease patients." International Psychogeriatrics 29, no. 7 (2017): 1227–28. http://dx.doi.org/10.1017/s1041610217000345.

Full text

Abstract:

We read the findings by Cecato et al. (2016) with great interest. In their study, naming the rhinoceros discriminated between patients with amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD) but not healthy controls (HC). Of note, HC participants were significantly younger than aMCI and AD patients. All participants were administered the original version of the Montreal Cognitive Assessment (MoCA) instrument.

APA, Harvard, Vancouver, ISO, and other styles

25

Crino, Peter B., Barry Greenberg, John A. Martin, Virginia M. Y. Lee, William D. Hill та John Q. Trojanowski. "β-Amyloid Peptide and Amyloid Precursor Proteins in Olfactory Mucosa of Patients with Alzheimer's Disease, Parkinson's Disease, and down Syndrome". Annals of Otology, Rhinology & Laryngology 104, № 8 (1995): 655–61. http://dx.doi.org/10.1177/000348949510400812.

Full text

Abstract:

Dystrophic neurites are present in olfactory epithelium (OE) of patients with Alzheimer's disease (AD), Parkinson's disease (PD), and Down syndrome (DS) and occasionally in normal individuals. Cultured olfactory neuroblasts from AD patients generate carboxy terminal amyloid precursor protein (APP) fragments that contain β-amyloid (Aβ), but it is not known if deposits of Aβ and/or APP fragments occur in the OE of individuals with or without AD, PD, or DS. To determine if Aβ accumulates in the OE in situ, we probed postmortem samples of olfactory mucosa from patients with AD, PD and AD (PD/AD),

APA, Harvard, Vancouver, ISO, and other styles

26

Rodriguez, Maria, and Salazar Torres. "Functional MRI for the Assessment of Brain Connectivity in Neurodegenerative Diseases: An Observational Study in Mexico City." Sriwijaya Journal of Radiology and Imaging Research 2, no. 2 (2024): 117–28. http://dx.doi.org/10.59345/sjrir.v2i2.164.

Full text

Abstract:

Introduction: Neurodegenerative diseases are characterized by progressive brain dysfunction and structural changes. Functional MRI (fMRI), a non-invasive imaging technique, offers the potential to assess brain connectivity and identify early biomarkers of these diseases. Methods: This observational study included patients with Alzheimer's disease (AD), Parkinson's disease (PD), and healthy controls in Mexico City. Resting-state fMRI data was acquired, and brain connectivity was analyzed using independent component analysis (ICA) and seed-based correlation analysis (SCA). Results: fMRI revealed

APA, Harvard, Vancouver, ISO, and other styles

27

Kusters, Cynthia D. J., Kimberly C. Paul, Aline Duarte Folle, et al. "Genetic risk scores and hallucinations in patients with Parkinson disease." Neurology Genetics 6, no. 5 (2020): e492. http://dx.doi.org/10.1212/nxg.0000000000000492.

Full text

Abstract:

ObjectiveWe examine the hypothesized overlap of genetic architecture for Alzheimer disease (AD), schizophrenia (SZ), and Parkinson disease (PD) through the use of polygenic risk scores (PRSs) with the occurrence of hallucinations in PD.MethodsWe used 2 population-based studies (ParkWest, Norway, and Parkinson's Environment and Gene, USA) providing us with 399 patients with PD with European ancestry and a PD diagnosis after age 55 years to assess the associations between 4 PRSs and hallucinations after 5 years of mean disease duration. Based on the existing genome-wide association study of othe

APA, Harvard, Vancouver, ISO, and other styles

28

Xu, Ke, Xue-Ling Dai, Han-Chang Huang, and Zhao-Feng Jiang. "Targeting HDACs: A Promising Therapy for Alzheimer's Disease." Oxidative Medicine and Cellular Longevity 2011 (2011): 1–5. http://dx.doi.org/10.1155/2011/143269.

Full text

Abstract:

Epigenetic modifications like DNA methylation and histone acetylation play an important role in a wide range of brain disorders. Histone deacetylases (HDACs) regulate the homeostasis of histone acetylation. Histone deacetylase inhibitors, which initially were used as anticancer drugs, are recently suggested to act as neuroprotectors by enhancing synaptic plasticity and learning and memory in a wide range of neurodegenerative and psychiatric disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD). To reveal the physiological roles of HDACs may provide us with a new perspective

APA, Harvard, Vancouver, ISO, and other styles

29

Camargo, Carlos Henrique Ferreira, Augusto Bronzini, Eduardo de Souza Tolentino, Camila Medyk, and Gustavo Leopold Schultz-Pereira. "Can the CERAD neuropsychological battery be used to assess cognitive impairment in Parkinson's disease?" Arquivos de Neuro-Psiquiatria 76, no. 3 (2018): 145–49. http://dx.doi.org/10.1590/0004-282x20180003.

Full text

Abstract:

ABSTRACT The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery was created to assess cognitive impairment in Alzheimer's disease (AD) but it is widely-used for various dementias. The aim of this study was to analyze the efficacy of using the CERAD battery in the assessment of patients with Parkinson's disease. Forty-nine patients with Parkinson's disease were divided into two groups (one with dementia and one without) using the Movement Disorder Society criteria for Parkinson's disease dementia. Cognitive deficits were assessed with the Clinical Deme

APA, Harvard, Vancouver, ISO, and other styles

30

Holroyd, Suzanne. "Hallucinations and Delusions in Dementia." International Psychogeriatrics 12, S1 (2000): 113–17. http://dx.doi.org/10.1017/s1041610200006876.

Full text

Abstract:

Hallucinations and delusions have been described in all types of dementia, including vascular dementia, Lewy body dementia, and dementia associated with Parkinson's disease. They have been recognized in Alzheimer's disease (AD) since the illness was first described (Alzheimer, 1957).

APA, Harvard, Vancouver, ISO, and other styles

31

Bibl, Mirko, Hermann Esselmann, Piotr Lewczuk та ін. "Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40ox% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia". International Journal of Alzheimer's Disease 2010 (2010): 1–7. http://dx.doi.org/10.4061/2010/761571.

Full text

Abstract:

We studied the diagnostic value of CSF Aβ42/tau versus low Aβ1–42% and high Aβ1–40ox% levels for differential diagnosis of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), respectively. CSF of 45 patients with AD, 15 with DLB, 21 with Parkinson's disease dementia (PDD), and 40 nondemented disease controls (NDC) was analyzed by Aβ-SDS-PAGE/immunoblot and ELISAs (Aβ42 and tau). Aβ42/tau lacked specificity in discriminating AD from DLB and PDD. Best discriminating biomarkers were Aβ1–42% and Aβ1–40ox% for AD and DLB, respectively. AD and DLB could be differentiated by both Aβ1–42% an

APA, Harvard, Vancouver, ISO, and other styles

32

Mohr, Erich, Irene Litvan, Jill Williams, Paul Fedio, and Thomas N. Chase. "Selective Deficits in Alzheimer and Parkinsonian Dementia: Visuospatial Function." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 17, no. 3 (1990): 292–97. http://dx.doi.org/10.1017/s0317167100030596.

Full text

Abstract:

ABSTRACT:Deficits in visuospatial cognition are frequently cited as an important component of the cognitive changes accompanying Parkinson's disease. To characterize possible differences between Parkinson's (PD) and Alzheimer's (AD) dementia, patients from both groups, matched for overall dementia severity, age and education, were contrasted neuropsychologically. Visuospatial tasks dissociated from memory, were significantly compromised in both patient groups. Differential impairment was evident on visuospatial abstraction and reasoning (Object Assembly), which was most deficient in PD. Visuos

APA, Harvard, Vancouver, ISO, and other styles

33

Abhishek, Prakash Yadav. "Pharmacological Interventions For Neurological Disorders: A Focus On Alzheimer's And Parkinson's Disease." International Journal in Pharmaceutical Sciences 2, no. 9 (2024): 743–67. https://doi.org/10.5281/zenodo.13765629.

Full text

Abstract:

Neurological disorders such as Alzheimer's and Parkinson's disease present major challenges due to their progressive nature and the limited efficacy of current treatments. This review paper presents a detailed examination of current pharmacological strategies and emerging therapies for AD and PD. For AD, the focus has been on cholinesterase inhibitors (ChEIs) and NMDA receptor antagonists, which aim to mitigate cognitive decline and slow disease progression. In PD, the standard treatments involve dopaminergic agents, including levodopa and dopamine agonists, which target motor symptoms. Recent

APA, Harvard, Vancouver, ISO, and other styles

34

Pimentel, Catarina, Liliana Batista-Nascimento, Claudina Rodrigues-Pousada, and Regina A. Menezes. "Oxidative Stress in Alzheimer's and Parkinson's Diseases: Insights from the YeastSaccharomyces cerevisiae." Oxidative Medicine and Cellular Longevity 2012 (2012): 1–9. http://dx.doi.org/10.1155/2012/132146.

Full text

Abstract:

Alzheimer's (AD) and Parkinson's (PD) diseases are the two most common causes of dementia in aged population. Both are protein-misfolding diseases characterized by the presence of protein deposits in the brain. Despite growing evidence suggesting that oxidative stress is critical to neuronal death, its precise role in disease etiology and progression has not yet been fully understood. Budding yeastSaccharomyces cerevisiaeshares conserved biological processes with all eukaryotic cells, including neurons. This fact together with the possibility of simple and quick genetic manipulation highlights

APA, Harvard, Vancouver, ISO, and other styles

35

Oshiro, Satoru, Masaki S. Morioka, and Masataka Kikuchi. "Dysregulation of Iron Metabolism in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis." Advances in Pharmacological Sciences 2011 (2011): 1–8. http://dx.doi.org/10.1155/2011/378278.

Full text

Abstract:

Dysregulation of iron metabolism has been observed in patients with neurodegenerative diseases (NDs). Utilization of several importers and exporters for iron transport in brain cells helps maintain iron homeostasis. Dysregulation of iron homeostasis leads to the production of neurotoxic substances and reactive oxygen species, resulting in iron-induced oxidative stress. In Alzheimer's disease (AD) and Parkinson's disease (PD), circumstantial evidence has shown that dysregulation of brain iron homeostasis leads to abnormal iron accumulation. Several genetic studies have revealed mutations in gen

APA, Harvard, Vancouver, ISO, and other styles

36

Maarouf, Chera L., Thomas G. Beach, Charles H. Adler, et al. "Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson's Disease Cases Lacking Alzheimer's Disease Pathology." Biomarker Insights 8 (January 2013): BMI.S11422. http://dx.doi.org/10.4137/bmi.s11422.

Full text

Abstract:

Identifying biomarkers that distinguish Parkinson's disease (PD) from normal control (NC) individuals has the potential to increase diagnostic sensitivity for the detection of early-stage PD. A previous proteomic study identified potential biomarkers in postmortem ventricular cerebrospinal fluid (V-CSF) from neuropathologically diagnosed PD subjects lacking Alzheimer's disease (AD) neuropathology. In the present study, we assessed these biomarkers as well as p-tau181, Aβ42, and S100B by ELISA in PD (n = 43) and NC (n = 49) cases. The p-tau181/Aβ42 ratio and ApoA-1 showed statistically signific

APA, Harvard, Vancouver, ISO, and other styles

37

Pilipovich, A. A., V. L. Golubev, Al B. Danilov, and R. R. Tyutina. "Role of biometals in pathogenesis treatment of Parkinson's disease (overview)." Medical alphabet, no. 1 (June 11, 2020): 21–27. http://dx.doi.org/10.33667/2078-5631-2020-1-21-27.

Full text

Abstract:

The role of exogenous factors in the occurrence of neurodegenerative diseases has been shown in many works: on the effects of radiation, neurotoxicants, pesticides and other organic and inorganic substances. One of the interesting and promising areas for studying the pathogenesis of neurodegeneration is the analysis of the composition and ratio of trace elements in various tissues and organs of a person. The influence of trace elements on the development of neurodegenerative diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease, amyotrophic lateral sclerosi

APA, Harvard, Vancouver, ISO, and other styles

38

A, Suganya, and S. L. Aarthy. "Alzheimer’s And Parkinson’s Disease Classification Using Deep Learning Based On MRI: A Review." International Journal of Communication Networks and Information Security (IJCNIS) 14, no. 1s (2023): 09–21. http://dx.doi.org/10.17762/ijcnis.v14i1s.5588.

Full text

Abstract:

Neurodegenerative disorders present a current challenge for accurate diagnosis and for providing precise prognostic information. Alzheimer’s disease (AD) and Parkinson's disease (PD), may take several years to obtain a definitive diagnosis. Due to the increased aging population in developed countries, neurodegenerative diseases such as AD and PD have become more prevalent and thus new technologies and more accurate tests are needed to improve and accelerate the diagnostic procedure in the early stages of these diseases. Deep learning has shown significant promise in computer-assisted AD and PD

APA, Harvard, Vancouver, ISO, and other styles

39

Kuszneruk, Julia, Katarzyna Chawrylak, Magdalena Kłusek, Maria Kubas, and Katarzyna Krzemińska. "What role do environmental factors play in the development of neurodegenerative diseases? A narrative review." Quality in Sport 18 (July 25, 2024): 53301. http://dx.doi.org/10.12775/qs.2024.18.53301.

Full text

Abstract:

Introduction and purposes: Degenerative diseases of the nervous system, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS). Environmental influences are significant contributors to the development of these conditions. The primary objective of this research was to examine key environmental factors that are suspected of their impact on the development of diseases, specifically lifestyle, medical conditions, diet and exposure to environmental pollution. Materials and Methods: A systematic literature search was conducted using PubMed and Google Scholar.

APA, Harvard, Vancouver, ISO, and other styles

40

Tsolaki, Magda, Konstantinos Fountoulakis, Elen Chantzi, and Aristides Kazis. "Risk Factors for Clinically Diagnosed Alzheimer's Disease: A Case-Control Study of a Greek Population." International Psychogeriatrics 9, no. 3 (1997): 327–41. http://dx.doi.org/10.1017/s104161029700447x.

Full text

Abstract:

Many efforts have been made to trace the causes of Alzheimer's disease (AD). There are, however, many points of controversy among reports from the same country as well as among reports from different countries. The current study is a case-control study to determine the risk factors in the development of AD in Greece. Sixty-five patients with AD and 69 age-matched controls were examined. All patients with AD fulfilled the DSM-IV criteria for AD and NINCDS-ADRDA criteria for probable AD. Demographic characteristics such as gender, current marital status, who he/she is living with, education, mai

APA, Harvard, Vancouver, ISO, and other styles

41

Remple, Michael S., Courtney H. Hayes, Chang Qing Kao, P. David Charles, Joseph Samir Neimat, and Peter Konrad. "Subthalamic Nucleus Neuronal Firing Rate Increases with Parkinson's Disease Progression." Neurosurgery 65, no. 2 (2009): 422. http://dx.doi.org/10.1227/01.neu.0000358737.15378.ad.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

CERCY, STEVEN P., and FREDERICK W. BYLSMA. "Lewy bodies and progressive dementia: A critical review and meta-analysis." Journal of the International Neuropsychological Society 3, no. 2 (1997): 179–94. http://dx.doi.org/10.1017/s1355617797001793.

Full text

Abstract:

Researchers disagree as to whether Lewy body disease (LBD) constitutes a variant of Alzheimer's (AD) or Parkinson's disease (PD), or alternatively, whether it is an independent disease process. The neuropathological, genetic, and clinical characteristics of LBD are reviewed and compared to those of AD and PD. Data for 150 cases of LBD reported in the literature were compiled and grouped according to neuropathological status. Patients with pure LBD (with limited or no concurrent AD pathology) tend to present at a younger age with extrapyramidal signs followed by dementia, whereas patients with

APA, Harvard, Vancouver, ISO, and other styles

43

Mohammadzadeh, Nahid, Chuang‐Kuo Wu, John E. Donahue, and Joseph H. Friedman. "Pathologically Confirmed Alzheimer's Disease Presenting as Clinical Parkinson's Disease, A Case Report." Movement Disorders Clinical Practice, June 22, 2024. http://dx.doi.org/10.1002/mdc3.14149.

Full text

Abstract:

AbstractBackgroundIt is well known that rare cases of Alzheimer's disease (AD) pathology may cause corticobasal or posterior cortical atrophy syndromes, and that cases with advanced AD may develop parkinsonism. However, reports of parkinsonism as an initial manifestation of AD have rarely been documented.ObjectivesTo demonstrate that a syndrome meeting all criteria for a clinical diagnosis of idiopathic Parkinson's disease (PD) may be an initial and years‐long sustained manifestation of pathologically confirmed AD.MethodsClinico‐pathological case.ResultsWe present a case with a 12‐year clinica

APA, Harvard, Vancouver, ISO, and other styles

44

Gopinath, Subash C. B., Hussaini Adam, M. K. Md Arshad, Adam Tijjani, Sreeramanan Subramaniam, and Uda Hashim. "An Update on Parkinson’s Disease and its Neurodegenerative Counterparts." Current Medicinal Chemistry 30 (April 3, 2023). http://dx.doi.org/10.2174/0929867330666230403085733.

Full text

Abstract:

Introduction: Neurodegenerative disorders are a group of diseases that cause nerve cell degeneration in the brain, resulting in a variety of symptoms and are not treatable with drugs. Parkinson's disease (PD), prion disease, motor neuron disease (MND), Huntington's disease (HD), spinal cerebral dyskinesia (SCA), spinal muscle atrophy (SMA), multiple system atrophy, Alzheimer's disease (AD), spinocerebellar ataxia (SCA) (ALS), pantothenate kinase-related neurodegeneration, and TDP-43 protein disorder are examples of neurodegenerative diseases. Dementia is caused by the loss of brain and spinal

APA, Harvard, Vancouver, ISO, and other styles

45

Rijul Mahesh Kharat. "Calcium Signaling in Neurodegeneration : A Review." International Journal of Scientific Research in Science and Technology, January 1, 2023, 113–20. http://dx.doi.org/10.32628/ijsrst2296105.

Full text

Abstract:

Neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and spinocerebellar ataxias (SCAs), pose a significant medical, social, financial, and scientific challenge. Recent data suggests that many of these illnesses have aberrant neuronal calcium (Ca2+) transmission. Normal aging causes alterations in neuronal Ca2+ signaling that are similar but less drastic. Here, we address the dysregulation of calcium in a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, a

APA, Harvard, Vancouver, ISO, and other styles

46

Relojo, Dennis. "On the road to therapeutics: Biological mechanisms of Parkinson's disease and Alzheimer's disease." August 1, 2015. https://doi.org/10.5281/zenodo.1289101.

Full text

Abstract:

This paper has sought to explore and summarise more recent findings on the genetic underpinnings of Parkinson's disease (AD) and Alzheimer's disease (AD). Recent studies have contributed to our understanding of these two devastating diseases. As the most common neurodegenerative disease, AD accounts for about two thirds of cases of dementia – ranging in various studies from 42 to 81 per cent of all dementia – with vascular causes and other neurodegenerative diseases such as Pick's disease and diffuse Lewy-body disease constituting the majority of the remaining cases. Me

APA, Harvard, Vancouver, ISO, and other styles

47

Minakawa, Eiko N. "Bidirectional Relationship Between Sleep Disturbances and Parkinson's Disease." Frontiers in Neurology 13 (July 18, 2022). http://dx.doi.org/10.3389/fneur.2022.927994.

Full text

Abstract:

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD). Both diseases share common clinical and pathological features: the gradual progression of neurological and psychiatric symptoms caused by neuronal dysfunction and neuronal cell death due to the accumulation of misfolded and neurotoxic proteins. Furthermore, both of them are multifactorial diseases in which both genetic and non-genetic factors contribute to the disease course. Non-genetic factors are of particular interest for the development of preventive and therapeutic approaches for

APA, Harvard, Vancouver, ISO, and other styles

48

Lau, Victor Z., Ifeoluwa O. Awogbindin, Dan Frenkel, Shawn N. Whitehead, and Marie‐Ève Tremblay. "A hypothesis explaining Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies overlap." Alzheimer's & Dementia 21, no. 6 (2025). https://doi.org/10.1002/alz.70363.

Full text

Abstract:

AbstractLewy body‐involving diseases (LBD) are commonly associated with Parkinson's disease (PD) featuring voluntary movement inhibition, due to dopaminergic neuron dysfunction in the substantia nigra. PD is clinically tracked through Lewy bodies (LB), composed of insoluble α‐synuclein aggregates sequestered with organelles, particularly inside neurons. However, α‐synuclein pathology also appears in incidental LBD, Parkinson's disease dementia, and dementia with LB (DLB). Incomplete explanations address how these clinical pathologies interrelate, LBD etiology variability, and frequently overla

APA, Harvard, Vancouver, ISO, and other styles

49

Oh, Daniel M., Jocelyn M. Jiao, Xinhui Wang, et al. "Early Motor Signs in Pathologically Verified Alzheimer's Disease and Lewy Body Disease." Movement Disorders Clinical Practice, January 23, 2025. https://doi.org/10.1002/mdc3.14341.

Full text

Abstract:

AbstractBackgroundThe neuropathologies of Alzheimer's disease (AD) and Lewy body disease (LBD) commonly co‐occur. Parkinsonism is the hallmark feature in LBD but it can be difficult to predict the presence of these co‐pathologies early in the course of clinical disease. Timely diagnosis has crucial implications, especially with the advent of disease‐modifying therapies.ObjectivesWe sought to define early motor features that predict the ultimate neuropathological diagnoses of normal, AD, AD with concurrent LB pathology, and pure LB.MethodsWe examined the associations between individuals’ early

APA, Harvard, Vancouver, ISO, and other styles

50

Chen, Sihui, Jiajia Fu, Xiaohui Lai, et al. "Analyses of hospitalization in Alzheimer's disease and Parkinson's disease in a tertiary hospital." Frontiers in Public Health 11 (May 4, 2023). http://dx.doi.org/10.3389/fpubh.2023.1159110.

Full text

Abstract:

BackgroundTo characterize the pattern of hospitalization in patients with Alzheimer's disease (AD) or Parkinson's disease (PD), and compare the differences to see whether AD patients and PD patients have a different picture of hospitalization.MethodsThe clinical features of all consecutive patients from January 2017 to December 2020 were reviewed. We identified AD patients and PD patients from an electronic database in a tertiary medical center.ResultsThe study group comprised 995 AD patients and 2,298 PD patients who were admitted to the hospital for the first time, and re-hospitalized 231 AD

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!